<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="bcns" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">bcns</book-part-id>
      <title-group>
        <title>Nevoid Basal Cell Carcinoma Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonyms: Basal Cell Nevus Syndrome (BCNS), Gorlin Syndrome, NBCCS</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Evans</surname>
            <given-names>D Gareth</given-names>
          </name>
          <degrees>MD, FRCP</degrees>
          <aff>Genomic Medicine<break/>Institute of Human Development<break/>University of Manchester<break/>Manchester Academic Health Science Centre<break/>Consultant in Medical Genetics, St Mary's Hospital and Christie Hospital<break/>Professor of Medical Genetics and Cancer Epidemiology, Manchester University<break/>Manchester, United Kingdom</aff>
          <email>gareth.evans@cmft.nhs.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farndon</surname>
            <given-names>Peter A</given-names>
          </name>
          <degrees>MD, FRCP</degrees>
          <aff>Clinical Genetics Unit<break/>Birmingham Women's Hospital<break/>Consultant Clinical Geneticist, West Midlands Regional Genetics Service<break/>Professor of Clinical Genetics, University of Birmingham<break/>Birmingham, United Kingdom</aff>
          <email>p.a.farndon@bham.ac.uk</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>20</day>
          <month>6</month>
          <year>2002</year>
        </date>
        <date date-type="updated">
          <day>1</day>
          <month>10</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="ncl" document-type="chapter">Neuronal Ceroid-Lipofuscinoses</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="nbs" document-type="chapter">Nicolaides-Baraitser Syndrome</related-object>
      <abstract id="bcns.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple jaw keratocysts, frequently beginning in the second decade of life, and/or basal cell carcinomas (BCCs) usually from the third decade onward. Approximately 60% of individuals have a recognizable appearance with macrocephaly, frontal bossing, coarse facial features, and facial milia. Most individuals have skeletal anomalies (e.g., bifid ribs, wedge-shaped vertebrae). Ectopic calcification, particularly in the falx, is present in more than 90% of affected individuals by age 20 years. Cardiac and ovarian fibromas occur in approximately 2% and 20% of individuals respectively. Approximately 5% of all children with NBCCS develop medulloblastoma (primitive neuroectodermal tumor [PNET]), generally the desmoplastic subtype. The risk of developing medulloblastoma is substantially higher in individuals with an <italic toggle="yes">SUFU</italic> pathogenic variant (33%) than in those with a <italic toggle="yes">PTCH1</italic> pathogenic variant (&#x0003c;2%). Peak incidence is at age one to two years. Life expectancy in NBCCS is not significantly different from average.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of NBCCS is established in a proband who fulfills existing diagnostic clinical criteria. Identification of a heterozygous pathogenic variant in <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> on molecular genetic testing establishes the diagnosis if clinical features are inconclusive.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Best provided by specialists experienced with the condition; keratocysts usually require surgical excision; early treatment of BCCs to ensure complete eradication of aggressive BCCs and to preserve normal tissue to prevent disfigurement; sonic hedgehog inhibitors such as vismodegib to treat severe BCCs; preservation of ovarian tissue whenever ovarian fibromas require surgical treatment.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Avoidance of direct sun exposure through the use of complete sunblock and covering of exposed skin with long sleeves, high collars, and hats.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitoring of head circumference throughout childhood; developmental assessment and physical examination every six months in the first years of life because of increased risk for medulloblastoma; in those over age eight years, orthopantogram every 12-18 months to identify jaw keratocysts; skin examination at least annually.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Radiotherapy if there are alternative treatments, especially in childhood; diagnostic x-rays should be used sparingly; direct sun exposure, excessive sun exposure increases the likelihood of developing BCCs.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Because of the need for surveillance for complications of NBCCS (medulloblastoma in children; jaw cysts and BCCs in adults) and the need to avoid sun exposure, clarification of the genetic status of at-risk relatives, including children, is appropriate.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>NBCCS is inherited in an autosomal dominant manner. Approximately 70%-80% of individuals with NBCCS have an affected parent and about 20%-30% have NBCCS as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. The offspring of an affected individual are at a 50% risk of inheriting NBCCS. Prenatal testing for pregnancies at risk is possible if the <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant has been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="bcns.Diagnosis">
        <title>Diagnosis</title>
        <sec id="bcns.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Nevoid basal cell carcinoma syndrome (NBCCS) <bold>should be suspected</bold> in individuals with the following findings:</p>
          <p>
            <bold>Major criteria</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Lamellar (sheet-like) calcification of the falx</bold> or clear evidence of calcification in an individual younger than age 20 years. Falx calcification is nearly always present and is visible on anteroposterior (AP) x-rays of the skull after age 20 years (see <bold>Notes regarding radiographs</bold>).</p>
            </list-item>
            <list-item>
              <p><bold>Jaw keratocyst</bold>. Odontogenic keratocyst histologically; seen on orthopantogram as an area of translucency</p>
            </list-item>
            <list-item>
              <p><bold>Palmar/plantar pits</bold> (two or more); particularly useful in diagnosis and more pronounced when the hands and feet are soaked in warm water for up to ten minutes. Pits may appear as white "punched-out" or pink "pin-prick" lesions.</p>
            </list-item>
          </list>
          <p><bold>Multiple basal cell carcinomas (BCCs)</bold> (&#x0003e;5 in a lifetime) or a BCC before age 30 years. Provision needs to be made for decreased risk of BCC in dark-skinned races and increased risk in whites living in hot sunny climates, particularly those with type 1 Celtic skin and red hair especially with the common <italic toggle="yes">MC1R</italic> variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1805007">rs1805007</ext-link>) that can modify age of onset for NBCCS [<xref ref-type="bibr" rid="bcns.REF.yasar.2015.708">Yasar et al 2015</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>First-degree relative with NBCCS</p>
            </list-item>
          </list>
          <p>
            <bold>Minor criteria</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Childhood medulloblastoma (also called primitive neuroectodermal tumor [PNET])</p>
              <p>Note: A consensus meeting consisting of US-based experts (with one French participant) has suggested changing medulloblastoma to a major criterion and allowing the diagnosis of NBCCS with only two minor criteria in addition to a major criterion [<xref ref-type="bibr" rid="bcns.REF.bree.2011.2091">Bree et al 2011</xref>]. The concern would be that this would reduce the specificity of diagnostic criteria, as individuals with medulloblastoma undergoing radiotherapy without NBCCS are likely to develop more than one BCC. Confining the medulloblastoma diagnosis to nodular/desmoplastic and disallowing BCCs occurring after radiotherapy as a major criterion may improve sensitivity without losing specificity. These changes have not yet been adopted.</p>
            </list-item>
            <list-item>
              <p>Lympho-mesenteric or pleural cysts</p>
            </list-item>
            <list-item>
              <p>Macrocephaly (OFC &#x0003e;97th centile)</p>
            </list-item>
            <list-item>
              <p>Cleft lip/palate</p>
            </list-item>
            <list-item>
              <p>Vertebral/rib anomalies observed on chest x-ray and/or spinal x-ray (see <bold>Notes regarding radiographs</bold>): bifid/splayed/extra ribs; bifid vertebrae</p>
            </list-item>
            <list-item>
              <p>Preaxial or postaxial polydactyly</p>
            </list-item>
            <list-item>
              <p>Ovarian/cardiac fibromas</p>
            </list-item>
            <list-item>
              <p>Ocular anomalies (cataract, developmental defects, and pigmentary changes of the retinal epithelium)</p>
            </list-item>
          </list>
          <p>
            <bold>Notes regarding radiographs</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>To verify a clinical diagnosis of NBCCS, AP and lateral x-rays of the skull, an orthopantogram, chest x-ray, and spinal x-ray are usually necessary.</p>
            </list-item>
            <list-item>
              <p>Clinicians should avoid using x-rays in childhood if the diagnosis is obvious without them or if a known pathogenic variant exists in the family.</p>
            </list-item>
            <list-item>
              <p>If radiographs have already been taken (i.e., before the diagnosis of NBCCS is being considered) it is preferable to obtain and review the original radiographs rather than repeat them because individuals with NBCCS are susceptible to x-irradiation.</p>
            </list-item>
            <list-item>
              <p>Even when present, bifid ribs, bifid vertebrae, and falx calcification are often not mentioned in formal reports of radiographic findings, as these can also be normal variations in the general population.</p>
            </list-item>
            <list-item>
              <p>X-ray findings may be helpful in suggesting or confirming the diagnosis in young children with cardiac fibromas, cleft lip/palate, polydactyly, or macrocephaly [<xref ref-type="bibr" rid="bcns.REF.debeer.2005.123">Debeer &#x00026; Devriendt 2005</xref>, <xref ref-type="bibr" rid="bcns.REF.veenstraknol.2005.126">Veenstra-Knol et al 2005</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="bcns.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of NBCCS <bold>is established</bold> in a proband with the following findings:</p>
          <list list-type="bullet">
            <list-item>
              <p>Two major diagnostic criteria and one minor diagnostic criterion or one major and three minor diagnostic criteria [<xref ref-type="bibr" rid="bcns.REF.evans.1993.460">Evans et al 1993</xref>]. A similar series of diagnostic criteria was proposed by <xref ref-type="bibr" rid="bcns.REF.kimonis.1997.299">Kimonis et al [1997]</xref>. No study has been able to assess which combination of diagnostic criteria represents the best trade-off between sensitivity and specificity.</p>
            </list-item>
            <list-item>
              <p>Identification of a heterozygous germline <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant on molecular genetic testing (<xref ref-type="table" rid="bcns.T.molecular_genetic_testing_used_in">Table 1</xref>). This finding establishes the diagnosis if clinical features are inconclusive.</p>
              <p>Note: Identification of an identical <italic toggle="yes">PTCH1</italic> pathogenic variant in two or more separate tumors but not present (or present at a lower-than-normal ratio) in lymphocyte DNA confirms the presence of mosaicism [<xref ref-type="bibr" rid="bcns.REF.evans.2007.424">Evans et al 2007</xref>].</p>
            </list-item>
          </list>
          <p>Molecular testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <p><bold>Single-gene testing.</bold> Suggested order:</p>
          <p>1. Sequence analysis of <italic toggle="yes">PTCH1</italic></p>
          <p>2. Gene-targeted deletion/duplication analysis of <italic toggle="yes">PTCH1</italic></p>
          <p>3. Sequence analysis of <italic toggle="yes">SUFU</italic></p>
          <p>4. Gene-targeted deletion/duplication analysis of <italic toggle="yes">SUFU</italic></p>
          <p>5. RNA analysis of <italic toggle="yes">PTCH1</italic></p>
          <p>Note: <italic toggle="yes">SUFU</italic> molecular testing should be considered first in families with medulloblastoma and without jaw keratocysts [<xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>].</p>
          <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">PTCH1, SUFU</italic> and other genes of interest (see <xref ref-type="sec" rid="bcns.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
          <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
          <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of NBCCS. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
          <table-wrap id="bcns.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Nevoid Basal Cell Carcinoma Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">PTCH1</italic>
                  </td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50%-85%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">6%-21%&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">RNA analysis&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 8</td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">SUFU</italic>
                  </td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">5%&#x000a0;<sup>9</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~1%&#x000a0;<sup>9</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown</td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_bcns.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">15%-27%&#x000a0;<sup>10</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="bcns.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="bcns" object-id="bcns.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="bcns.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="bcns.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="bcns.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="bcns.TF.1.4">
                <label>4. </label>
                <p>Sequence analysis of exons 2-23 with intron-exon junctions and one of the splice forms of exon 1 detects pathogenic variants in 50%-85% of individuals with typical clinical findings of NBCCS. Individuals and families with no other features apart from multiple BCCs have a very small probability of having a <italic toggle="yes">PTCH1</italic> pathogenic variant [<xref ref-type="bibr" rid="bcns.REF.klein.2005.611">Klein et al 2005</xref>, <xref ref-type="bibr" rid="bcns.REF.marsh.2005.283">Marsh et al 2005</xref>].</p>
              </fn>
              <fn id="bcns.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="bcns.TF.1.6">
                <label>6. </label>
                <p>Eight of 38 individuals with NBCCS had large deletions that were not identified using sequence analysis [<xref ref-type="bibr" rid="bcns.REF.nagao.2011.196">Nagao et al 2011</xref>].</p>
              </fn>
              <fn id="bcns.TF.1.7">
                <label>7. </label>
                <p>Appropriately processed RNA can be subjected to RT-PCR and sequence analysis to identify abnormal transcripts resulting from pathogenic variants not detectable or interpretable by sequence analysis of genomic DNA alone.</p>
              </fn>
              <fn id="bcns.TF.1.8">
                <label>8. </label>
                <p>Rare deep intronic variants that alter splicing are predicted to cause loss of function of protein patched homolog 1 [<xref ref-type="bibr" rid="bcns.REF.bholah.2014.477">Bholah et al 2014</xref>].</p>
              </fn>
              <fn id="bcns.TF.1.9">
                <label>9. </label>
                <p>
                  <xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al [2014]</xref>
                </p>
              </fn>
              <fn id="bcns.TF.1.10">
                <label>10. </label>
                <p>After sequencing and MLPA of both <italic toggle="yes">PTCH1</italic> and <italic toggle="yes">SUFU</italic> as well as RNA testing of <italic toggle="yes">PTCH1</italic>, 47 (27%) of 171 individuals with NBCCS had no identified pathogenic variant [<xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v21/n10/full/ejhg2012299a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="bcns.REF.lo_muzio.2013">Lo Muzio et al 2013</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="bcns.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="bcns.Clinical_Description">
          <title>Clinical Description</title>
          <p>More than 100 features that are variable within and among families have been associated with nevoid basal cell carcinoma syndrome (NBCCS) [<xref ref-type="bibr" rid="bcns.REF.farndon.2004">Farndon 2004</xref>].</p>
          <p>Findings in their usual order of manifestation:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Macrocephaly.</bold> The first feature likely to be observed is relative macrocephaly. A large proportion of babies with NBCCS require delivery by caesarean section because of large head size. After birth, the head growth pattern often resembles that of arrested hydrocephalus, but hydrocephaly requiring treatment is rare. Head circumference increases above the 97th centile until age ten to 18 months and then maintains its centile.</p>
            </list-item>
            <list-item>
              <p><bold>Other congenital malformations,</bold> found in approximately 5%, include cleft lip/palate (5%), polydactyly, and severe eye anomalies. Eye findings include strabismus, cataract, orbital cyst, microphthalmia, and pigmentary changes of the retinal epithelium [<xref ref-type="bibr" rid="bcns.REF.black.2003.478">Black et al 2003</xref>, <xref ref-type="bibr" rid="bcns.REF.ragge.2005.988">Ragge et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Gross motor delay.</bold> There is often some delay in motor milestones; most individuals catch up by about age five years. No published psychometric evidence for global delay exists.</p>
            </list-item>
            <list-item>
              <p><bold>Medulloblastoma.</bold> Approximately 5% of all individuals with NBCCS develop the childhood brain malignancy medulloblastoma (now often called primitive neuroectodermal tumor [PNET]) [<xref ref-type="bibr" rid="bcns.REF.cowan.1997.141">Cowan et al 1997</xref>]. The tumor tends to be of desmoplastic histology [<xref ref-type="bibr" rid="bcns.REF.amlashi.2003.618">Amlashi et al 2003</xref>] and to have a favorable prognosis. Peak incidence of medulloblastoma in NBCCS is at approximately age one to two years, compared to seven years in its sporadic form [<xref ref-type="bibr" rid="bcns.REF.cowan.1997.141">Cowan et al 1997</xref>, <xref ref-type="bibr" rid="bcns.REF.amlashi.2003.618">Amlashi et al 2003</xref>].</p>
              <p>More recently, nonsense and missense variants and multiexon deletion of <italic toggle="yes">SUFU</italic> were identified in three families with classic NBCCS features; one individual in each family had medulloblastoma [<xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>]. <italic toggle="yes">SUFU</italic>-related NBCCS is associated with a high risk for medulloblastoma of up to 33% (3/9) and a high meningioma risk post radiation. The risk for medulloblastoma in <italic toggle="yes">PTCH1</italic>-related NBCCS was lower than 2% [<xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Facies.</bold> Approximately 60% of individuals with a <italic toggle="yes">PTCH1</italic> pathogenic variant have a recognizable appearance with frontal bossing, coarse facial features, and facial milia. Facial features are likely more subtle in individuals with an <italic toggle="yes">SUFU</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p><bold>Skeletal features.</bold> Congenital bone anomalies are present at birth but will not be evident clinically in a newborn. The shoulders slope downward. Most individuals have skeletal anomalies identified on radiographs (e.g., bifid ribs, wedge-shaped vertebrae). Severe skeletal defects resulting from multiple rib/vertebral anomalies have been reported but are uncommon, as is open spina bifida.</p>
              <p>Ectopic calcification, particularly in the falx, is present in more than 90% of individuals by age 20 years [<xref ref-type="bibr" rid="bcns.REF.ratcliffe.1995.596">Ratcliffe et al 1995</xref>, <xref ref-type="bibr" rid="bcns.REF.kimonis.2004.495">Kimonis et al 2004</xref>]. Sella calcification, when present, is visible on lateral x-rays of the skull.</p>
            </list-item>
            <list-item>
              <p><bold>Jaw keratocysts.</bold> Approximately 90% of individuals with <italic toggle="yes">PTCH1</italic>-related NBCCS develop multiple jaw keratocysts. They can occur as early as age five years, but the peak occurrence is in the teenage years. Jaw keratocysts usually present as painless swellings. Untreated, they can lead to major tooth disruption and fracture of the jaw. Jaw cysts rarely occur after age 30 years.</p>
              <p>Jaw cysts have not been reported in individuals with <italic toggle="yes">SUFU</italic>-related NBCCS [<xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>].</p>
              <p>A rare malignant transformation of a keratocyst called ameloblastoma has been reported in individuals with NBCCS at least six times [<xref ref-type="bibr" rid="bcns.REF.ponti.2012.177">Ponti et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Basal cell carcinomas (BCCs).</bold> Brownish/pink/orange basal cell nevi may occur in early childhood and may lie quiescent without evidence of aggressive behavior. The histologic appearance is that of a typical BCC which, when excised, can be the first, unexpected finding of NBCCS in simplex cases (i.e., affected individuals with no known family history of NBCCS), especially children. Active BCCs may grow from existing basal cell nevi that may be numerous, or typical BCCs may appear from virtually blemish-free skin. BCCs may also crust, bleed, and ulcerate, or may present as a localized infection.</p>
              <p>BCCs can occur in early childhood, but in general do not present until the late teens or early adulthood. They occur more frequently with age, although 10% of individuals with NBCCS never develop a BCC. Individuals with type 1 skin (white skin that burns, but never tans, e.g., Celtic skin) and individuals with excessive ultraviolet light exposure seem especially prone to developing large numbers of BCCs. Clinically some affected individuals appear to be particularly radiosensitive, with new BCCs appearing in the field of radiation following radiotherapy.</p>
            </list-item>
            <list-item>
              <p><bold>Other skin manifestations</bold> include meibomian cysts in the eyelids, sebaceous cysts, and dermoid cysts. Skin tags (especially around the neck) often have the histologic appearance of BCCs but do not act aggressively.</p>
            </list-item>
            <list-item>
              <p><bold>Other tumors.</bold> Cardiac and ovarian fibromas occur, respectively, in approximately 2% and 20% of females [<xref ref-type="bibr" rid="bcns.REF.evans.1993.460">Evans et al 1993</xref>, <xref ref-type="bibr" rid="bcns.REF.gorlin.2004.530">Gorlin 2004</xref>]. Cardiac fibromas are usually present at birth or soon after. They can be asymptomatic or can cause arrhythmia or obstruction of cardiac flow. Rhabdomyomas may occur at other sites as well as in the heart [<xref ref-type="bibr" rid="bcns.REF.watson.2004.716">Watson et al 2004</xref>].</p>
              <p>Ovarian fibromas occur with both <italic toggle="yes">SUFU</italic> and <italic toggle="yes">PTCH1</italic>-related NBCCS. They are usually an incidental finding on ultrasound examination or at caesarean section. They may cause torsion of the ovary but are not thought to affect fertility. They can become large and calcified; however, malignant transformation is uncommon.</p>
              <p>The risk for other malignant tumors is not clearly increased, although lymphoma [<xref ref-type="bibr" rid="bcns.REF.pereira.2011.388">Pereira et al 2011</xref>] and meningioma have been reported [<xref ref-type="bibr" rid="bcns.REF.kijima.2012.565">Kijima et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Morbidity/mortality.</bold> Life expectancy in NBCCS is not significantly different from average [<xref ref-type="bibr" rid="bcns.REF.wilding.2012.264">Wilding et al 2012</xref>]. The major problem is with the cosmetic effect of treatment of multiple skin tumors and usually, to a lesser extent, treatment of jaw keratocysts. A poor cosmetic outcome can lead to social difficulties, including difficulty maintaining employment.</p>
            </list-item>
          </list>
        </sec>
        <sec id="bcns.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Early reports did not find a genotype-phenotype correlation [<xref ref-type="bibr" rid="bcns.REF.wicking.1997.21">Wicking et al 1997</xref>]. In particular there is no evidence for genotype affecting age at onset of BCCs [<xref ref-type="bibr" rid="bcns.REF.jones.2011">Jones et al 2011</xref>].</p>
        </sec>
        <sec id="bcns.Penetrance">
          <title>Penetrance</title>
          <p>Although NBCCS shows intra- and interfamilial variation in expression, experience clinically and from molecular testing is compatible with complete penetrance [Author, personal observation]. A previous report of reduced penetrance in a family with medulloblastoma based on <italic toggle="yes">PTCH1</italic> linkage analysis was refuted when the family was shown to have an <italic toggle="yes">SUFU</italic> pathogenic variant. [<xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>]. The penetrance of <italic toggle="yes">SUFU</italic> pathogenic variants is more difficult to determine, but is likely to be reduced.</p>
        </sec>
        <sec id="bcns.Prevalence">
          <title>Prevalence</title>
          <p>Few studies of NBCCS prevalence exist. The most quoted prevalence figure, 1:57,000, comes from a study of a UK population of four million in northwest England [<xref ref-type="bibr" rid="bcns.REF.evans.1991b.959">Evans et al 1991b</xref>]. Since publication of the study, an increased awareness of NBCCS and consequent increased diagnosis has led to a revision of that figure to nearer to 1:30,827 [<xref ref-type="bibr" rid="bcns.REF.evans.2010.327">Evans et al 2010</xref>]. The true figure may be even higher, as individuals with milder features may not be recognized.</p>
          <p>A study in Australia gave a minimum prevalence of 1:164,000 [<xref ref-type="bibr" rid="bcns.REF.shanley.1994.282">Shanley et al 1994</xref>].</p>
          <p>Birth incidence has recently been confirmed to be as high as1:18,976 [<xref ref-type="bibr" rid="bcns.REF.evans.2010.327">Evans et al 2010</xref>].</p>
        </sec>
      </sec>
      <sec id="bcns.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><xref ref-type="bibr" rid="bcns.REF.ming.2002.297">Ming et al [2002]</xref> reported a heterozygous <italic toggle="yes">PTCH1</italic> missense pathogenic variant in five of 100 unrelated probands with <related-object link-type="booklink" source-id="gene" document-id="hpe-overview" document-type="chapter">holoprosencephaly</related-object>. The authors hypothesized that the pathogenic missense variant would lead to enhanced repressive activity of <italic toggle="yes">PTCH1</italic> on the hedgehog signaling pathway, unlike the mechanism in NBCCS in which the pathway is activated, usually by haploinsufficiency for protein patched homolog 1 encoded by <italic toggle="yes">PTCH1</italic>. <xref ref-type="bibr" rid="bcns.REF.ribeiro.2006.2584">Ribeiro et al [2006]</xref> reported four further <italic toggle="yes">PTCH1</italic> pathogenic missense variants associated with holoprosencephaly.</p>
      </sec>
      <sec id="bcns.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis depends on the mode of presentation.</p>
        <p><bold>Macrocephaly.</bold> If the proband is a baby with macrocephaly and other birth defects, a limited number of overgrowth syndromes including Sotos syndrome and Beckwith-Wiedemann syndrome need to be considered:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="sotos" document-type="chapter"><bold>Sotos syndrome</bold></related-object> is characterized by a typical facial appearance, intellectual impairment, and overgrowth (increased height and head circumference). It is associated with neonatal jaundice, scoliosis, seizures, strabismus, conductive hearing loss, congenital cardiac anomalies, renal anomalies, and behavioral problems. The risk for sacrococcygeal teratoma and neuroblastoma is slightly increased. Approximately 80%-90% of individuals with Sotos syndrome have a demonstrable <italic toggle="yes">NSD1</italic> pathogenic variant. Sotos syndrome is inherited in an autosomal dominant manner, with more than 95% of individuals having a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="bws" document-type="chapter"><bold>Beckwith-Wiedemann syndrome</bold></related-object> is a disorder of growth characterized by macrosomia (large body size), macroglossia, visceromegaly, embryonal tumors (e.g., Wilms tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma), omphalocele, neonatal hypoglycemia, ear creases/pits, adrenocortical cytomegaly, and renal abnormalities (e.g., medullary dysplasia, nephrocalcinosis, medullary sponge kidney, and nephromegaly). Macroglossia and macrosomia are generally present at birth but may have postnatal onset. Growth rate slows around age seven to eight years. Hemihyperplasia may affect segmental regions of the body or selected organs and tissues. The diagnosis relies primarily on clinical findings. Beckwith-Wiedemann syndrome is associated with abnormal regulation of gene transcription in the imprinted domain on chromosome 11p15.5.</p>
          </list-item>
          <list-item>
            <p><bold>Isolated hydrocephaly</bold> or <bold>megalencephaly</bold> may be distinguished by clinical examination, family history, and x-rays.</p>
          </list-item>
        </list>
        <p><bold>Basal cell carcinomas (BCCs).</bold> If the initial presentation is multiple BCCs, clinical examination and radiographs should nearly always establish the diagnosis of NBCCS. Other inherited disorders with similar skin findings include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Brooke-Spiegler syndrome, characterized by trichoepitheliomas, milia, and cylindromas, presents in the second or third decade and is inherited in an autosomal dominant manner (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/605041">605041</ext-link>). The milia are miniature trichoepitheliomas and appear only in sun-exposed areas.</p>
          </list-item>
          <list-item>
            <p>Bazex syndrome, characterized by multiple BCCs, follicular atrophoderma on the dorsum of hands and feet, decreased sweating, and hypotrichosis (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/301845">301845</ext-link>). The pitting on the backs of the hands is reminiscent of orange peel and quite unlike the palmar and plantar pits of NBCCS. The inheritance pattern is either autosomal dominant or X-linked.</p>
          </list-item>
          <list-item>
            <p>Rombo syndrome, a dominantly inherited condition similar to Bazex syndrome, reported in a single family (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/180730">180730</ext-link>). Skin findings are vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, BCCs, and peripheral vasodilation with cyanosis. The skin is normal until later childhood; BCCs develop in adulthood. Sweating is normal.</p>
          </list-item>
          <list-item>
            <p>An autosomal dominant or X-linked syndrome of hypotrichosis and BCCs reported in a single family [<xref ref-type="bibr" rid="bcns.REF.oley.1992.799">Oley et al 1992</xref>] (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/301845">301845</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Autosomal dominant inheritance of multiple basal cell carcinomas in the absence of other features</p>
          </list-item>
        </list>
        <p>Acquired causes of multiple BCCs include arsenic exposure.</p>
        <p><bold>Jaw keratocysts.</bold> If the initial presentation is jaw keratocysts, clinical examination and radiographs should nearly always establish the diagnosis of NBCCS. In addition to examination of the child, a medical history and examination of the parents is advised.</p>
        <p><bold>Medulloblastoma.</bold> Children presenting with medulloblastoma need to be assessed for NBCCS, particularly if they are younger than age three years and/or have desmoplastic histology. In addition to examining the child, a medical history and examination of the parents is advised.</p>
        <p>Children with nodular or desmoplastic medulloblastoma also need to be assessed for a germline heterozygous pathogenic variant in <italic toggle="yes">SUFU</italic> [<xref ref-type="bibr" rid="bcns.REF.brugi_res.2012.2087">Brugi&#x000e8;res et al 2012</xref>]. Brugi&#x000e8;res and colleagues demonstrated that 3/3 individuals with nodular medulloblastoma and 4/20 individuals with desmoplastic medulloblastoma caused by a germline heterozygous pathogenic variant in <italic toggle="yes">SUFU</italic> had some features of NBCCS. Furthermore, a germline pathogenic variant in <italic toggle="yes">SUFU</italic> is associated with macrocephaly and 1/8 individuals with an <italic toggle="yes">SUFU</italic> heterozygous germline pathogenic variant who had medulloblastoma developed BCCs in the radiation field [<xref ref-type="bibr" rid="bcns.REF.brugi_res.2012.2087">Brugi&#x000e8;res et al 2012</xref>].</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="mdel9q22_3" document-type="chapter"><bold>9q22.3 microdeletion</bold></related-object><bold>.</bold> Large chromosomal deletions that involve <italic toggle="yes">PTCH1</italic> are the cause of 9q22.3 microdeletion syndrome. This syndrome is characterized by developmental delay and/or intellectual disability, metopic craniosynostosis, obstructive hydrocephalus, pre- and postnatal macrosomia, and seizures, in addition to the features of NBCCS [<xref ref-type="bibr" rid="bcns.REF.muller.2012.391">Muller et al 2012</xref>].</p>
      </sec>
      <sec id="bcns.Management">
        <title>Management</title>
        <sec id="bcns.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with nevoid basal cell carcinoma syndrome (NBCCS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Baseline measurement of head circumference, preferably with plotting on a chart that accounts for height. Evidence of rapid increase in centiles should prompt further investigation to exclude hydrocephalus.</p>
            </list-item>
            <list-item>
              <p>Physical examination for birth defects of clinical significance (e.g., orofacial clefts, polydactyly)</p>
            </list-item>
            <list-item>
              <p>X-rays to evaluate for rib and vertebral anomalies and falx calcification</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation for evidence of strabismus, cataract, orbital cyst, microphthalmia, and pigmentary changes of the retinal epithelium</p>
            </list-item>
            <list-item>
              <p>Evaluation by a dentist or orthodontist familiar with NBCCS; jaw x-ray (orthopantogram) in individuals age eight years or older to evaluate for jaw keratocysts and other anomalies</p>
            </list-item>
            <list-item>
              <p>Skin examination by a dermatologist familiar with NBCCS</p>
            </list-item>
            <list-item>
              <p>Ultrasound examination of the ovaries to evaluate for ovarian fibromas prior to pregnancy</p>
            </list-item>
            <list-item>
              <p>Echocardiography in the first year of life to evaluate for cardiac fibromas</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
          <p>Because mesenteric and pleural cysts are rare, evaluation is not necessary in the absence of symptoms.</p>
        </sec>
        <sec id="bcns.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Manifestations should be treated by specialists (e.g., oral surgeon, dermatologist, plastic surgeon, pediatrician, clinical geneticist) experienced with the condition.</p>
          <list list-type="bullet">
            <list-item>
              <p>Keratocysts usually require surgical excision.</p>
            </list-item>
            <list-item>
              <p>Early treatment of BCCs is essential to prevent long-term cosmetic problems, particularly on the face. The priorities are to ensure complete eradication of aggressive BCCs, and to preserve normal tissue to prevent disfigurement. Surgical excision is supplemented by a number of other possible treatments including cryotherapy and laser treatment for early lesions and photodynamic therapy. Photodynamic therapy is particularly suitable for thin lesions of &#x0003c;2 mm on ultrasound [<xref ref-type="bibr" rid="bcns.REF.bassetseguin.2014.626">Basset-Seguin et al 2014</xref>]. Surgical treatment using Mohs' microsurgery [<xref ref-type="bibr" rid="bcns.REF.mohs.1980.777">Mohs et al 1980</xref>] appears particularly effective.</p>
              <p>Systemic treatment with retinoids (e.g., etretinate) is possible but often not well tolerated.</p>
              <p>Treatment of individuals with severe BCC manifestations and/or advanced lesions with sonic hedgehog inhibitors such as vismodegib is now possible. Although side effects are common and quite severe there is a high resolution of advanced lesions and reduction in new BCCs [<xref ref-type="bibr" rid="bcns.REF.sekulic.2012.2171">Sekulic et al 2012</xref>]. Sonic hedgehog inhibitors may be particularly helpful with lesions around the eyes [<xref ref-type="bibr" rid="bcns.REF.ozgur.2015.220">Ozgur et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>Cardiac fibromas may be asymptomatic and can be monitored by a pediatric cardiologist.</p>
            </list-item>
            <list-item>
              <p>If ovarian fibromas require surgical treatment, preservation of ovarian tissue is recommended, although it involves a risk of recurrence [<xref ref-type="bibr" rid="bcns.REF.seracchioli.2001.1261">Seracchioli et al 2001</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="bcns.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Affected individuals should cover up exposed skin by wearing long sleeves, high collars, and hats; complete sunblock should be used.</p>
        </sec>
        <sec id="bcns.Surveillance">
          <title>Surveillance</title>
          <p>Head circumference should be followed throughout childhood and plotted on appropriate growth charts. Rapid enlargement should prompt evaluation for possible hydrocephalus.</p>
          <p>Awareness of the risk of medulloblastoma in the first years of life is important and may justify developmental assessment and physical examination every six months. No evidence for the efficacy of regular neuroimaging exists; frequent computed tomography (CT) scans should be avoided because of risks associated with radiation sensitivity. A recent consensus meeting has suggested annual head MRI scans until age eight years in affected children [<xref ref-type="bibr" rid="bcns.REF.bree.2011.2091">Bree et al 2011</xref>], but this would require general anesthesia for many children and is probably not now justified in <italic toggle="yes">PTCH1</italic>-related NBCCS with only a 2% risk. However, it may well be justified in infants with <italic toggle="yes">SUFU</italic> pathogenic variants [<xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>].</p>
          <p>No other tumors occur at a frequency that warrants surveillance above that offered to members of the general population.</p>
          <p>Orthopantogram is indicated every 12-18 months in individuals older than age eight years to identify jaw keratocysts.</p>
          <p>Skin should be examined at least annually; some physicians recommend skin examination by a professional every three to four months.</p>
        </sec>
        <sec id="bcns.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Use of radiotherapy can lead to the development of thousands of BCCs in the radiation field [<xref ref-type="bibr" rid="bcns.REF.strong.1977.1861">Strong 1977</xref>, <xref ref-type="bibr" rid="bcns.REF.evans.1991a.643">Evans et al 1991a</xref>] and therefore should be avoided if there are alternative treatments, especially in childhood. If the treating team believes that no other treatment modality is possible, radiotherapy should be used through as few skin ports as possible.</p>
          <p>Diagnostic x-rays should be used sparingly.</p>
          <p>Individuals with NBCCS should be advised to avoid direct sun exposure as much as possible. Excessive sun exposure increases the likelihood of developing BCCs.</p>
        </sec>
        <sec id="bcns.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives, including children, of an affected individual in order to identify as early as possible those who would benefit from surveillance (see <xref ref-type="sec" rid="bcns.Surveillance">Surveillance</xref>) for complications of NBCCS (most notably medulloblastoma in children and jaw cysts and BCCs in adults) and the need to avoid x-rays and sun exposure (see <xref ref-type="sec" rid="bcns.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</xref>).</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variant in the family is known;</p>
            </list-item>
            <list-item>
              <p>Clinical examination and x-rays of the skull for calcification if the pathogenic variant in the family is not known; these may be less likely to clarify the genetic status in a very young child because of the age-related features of NBCCS.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="bcns.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="bcns.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Since individuals with NBCCS have a large head circumference, a woman who is carrying an affected fetus should be assessed for the need for either early induction of labor or caesarean section delivery due to cephalopelvic disproportion.</p>
        </sec>
        <sec id="bcns.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Photodynamic therapy (with infra-red light) showed early promise and appears safe [<xref ref-type="bibr" rid="bcns.REF.haylett.2003.337">Haylett et al 2003</xref>]. A recent study showed outcomes in 33 individuals with NBCCS treated with photodynamic therapy (PDT) with a near-60% control rate [<xref ref-type="bibr" rid="bcns.REF.loncaster.2009.502">Loncaster et al 2009</xref>].</p>
          <p>Aminolevulinic acid has been investigated [<xref ref-type="bibr" rid="bcns.REF.itkin.2004.1054">Itkin &#x00026; Gilchrest 2004</xref>, <xref ref-type="bibr" rid="bcns.REF.oseroff.2005.60">Oseroff et al 2005</xref>]. It is usually used in conjunction with PDT [<xref ref-type="bibr" rid="bcns.REF.loncaster.2009.502">Loncaster et al 2009</xref>].</p>
          <p>Topical treatment with 5-fluorouracil (Efudex<sup>&#x000ae;</sup>) or imiquimod (5%) has been investigated [<xref ref-type="bibr" rid="bcns.REF.kagy.2000.577">Kagy &#x00026; Amonette 2000</xref>, <xref ref-type="bibr" rid="bcns.REF.marks.2001.807">Marks et al 2001</xref>, <xref ref-type="bibr" rid="bcns.REF.stockfleth.2002.569">Stockfleth et al 2002</xref>]. A recent review suggested control rates approaching 90% for superficial BCCs and 50% for aggressive or nodular BCCs with imiquimod [<xref ref-type="bibr" rid="bcns.REF.alessi.2009.961">Alessi et al 2009</xref>].</p>
          <p>Topical 5-fluorouracil appears effective for superficial multicentric BCCs without follicular involvement but should not be used for deeply invasive BCCs.</p>
          <p>Recently topical use of sonic hedgehog antagonists has entered clinical trials and is showing promise [<xref ref-type="bibr" rid="bcns.REF.saran.2010.1003">Saran 2010</xref>]. Systemic use of sonic hedgehog antagonists in individuals with NBCCS who have advanced or refractory BCCs has also been effective [<xref ref-type="bibr" rid="bcns.REF.sekulic.2012.2171">Sekulic et al 2012</xref>, <xref ref-type="bibr" rid="bcns.REF.tang.2012.2180">Tang et al 2012</xref>], with a 43% response rate in 63 affected individuals with locally advanced BCCs. Response rates were very high in individuals with NBCCS but 53% discontinued therapy because of adverse side effects [<xref ref-type="bibr" rid="bcns.REF.tang.2012.2180">Tang et al 2012</xref>]. Sonic hedgehog antagonists may be particularly useful for periocular lesions [<xref ref-type="bibr" rid="bcns.REF.ozgur.2015.220">Ozgur et al 2015</xref>]. A recent report suggests that anti-sonic hedgehog agents may also resolve keratocysts when given for BCC treatment [<xref ref-type="bibr" rid="bcns.REF.goldberg.2011.839">Goldberg et al 2011</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="bcns.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="bcns.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Nevoid basal cell carcinoma syndrome (NBCCS) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="bcns.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Approximately 70%-80% of individuals diagnosed with NBCCS have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with NBCCS may have the disorder as the result of a <italic toggle="yes">de novo PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant. The proportion of individuals with NBCCS with a <italic toggle="yes">de novo</italic> pathogenic variant is approximately 20%-30%.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include a detailed skin examination, AP and lateral x-rays of the skull, chest x-ray, and spine x-ray. Molecular genetic testing can be used to clarify the genetic status of a parent when a <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant has been identified in the proband or other affected family member.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with NBCCS may appear to be negative as a result of failure to recognize the disorder in a family member, early death of the parent before the onset of symptoms, or late onset of the disorder in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or molecular genetic testing has been performed on the parents of the proband.</p>
            </list-item>
            <list-item>
              <p>Note: If the parent is the individual in whom the pathogenic variant first occurred, s/he may have somatic mosaicism for the pathogenic variant, and may be mildly/minimally affected.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to a sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism. Although this has not been proven in NBCCS, low risks have been confirmed in the analogous situation in individuals with <related-object link-type="booklink" source-id="gene" document-id="nf2" document-type="chapter">neurofibromatosis type 2</related-object> (NF2) [<xref ref-type="bibr" rid="bcns.REF.evans.2007.424">Evans et al 2007</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with NBCCS has a 50% chance of inheriting the <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The offspring of an individual with mild NBCCS caused by somatic mosaicism may have a less than 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
          </list>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected, his or her family members may be at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="bcns.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="bcns.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Genetic cancer risk assessment and counseling.</bold> For comprehensive descriptions of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without molecular genetic testing, see , see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</ext-link> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with NBCCS has the pathogenic variant or clinical evidence of the disorder, the <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption can also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>Predictive testing of individuals during childhood.</bold> Because of the need for surveillance for complications of NBCCS (most notably medulloblastoma) during childhood, clarification of the genetic status of at-risk individuals during childhood is appropriate. Clinical examination and x-rays of the skull for calcification may be less likely to clarify the genetic status in a very young child because of the age-related features of NBCCS. Molecular genetic testing may be considered if a <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU</italic> pathogenic variant has been identified in an affected family member.</p>
          <p><bold>Predictive testing of adults.</bold> Clinical examination and x-rays frequently act as a "genetic test" in an apparently unaffected individual. Individuals need to be aware of the predictive implications of these examinations as well as those of molecular genetic testing of <italic toggle="yes">PTCH1</italic> or <italic toggle="yes">SUFU.</italic></p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="bcns.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">PTCH1 or SUFU</italic> pathogenic variant has been identified in an affected family member, prenatal for a pregnancy at increased risk testing and preimplantation genetic diagnosis for nevoid basal cell carcinoma syndrome are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="bcns.Resources">
        <title>Resources</title>
      </sec>
      <sec id="bcns.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="bcns.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The comparatively young mean age at onset of medulloblastoma in individuals with nevoid basal cell carcinoma syndrome (NBCCS) (age 2 years vs 7 years in the general population) and the loss of the normal <italic toggle="yes">PTCH1</italic> allele in tumors [<xref ref-type="bibr" rid="bcns.REF.cowan.1997.141">Cowan et al 1997</xref>] confirm <italic toggle="yes">PTCH1</italic> as a tumor suppressor in medulloblastoma as well as in basal cell carcinoma (BCC). Inactivation of the normal allele also appears to be the mechanism responsible for jaw cysts, whereas the congenital malformations are likely to result from alterations in the concentration of the protein patched homolog 1 in the extremely dosage-sensitive hedgehog signaling pathway [<xref ref-type="bibr" rid="bcns.REF.villavicencio.2000.1047">Villavicencio et al 2000</xref>].</p>
          <p>Note: <italic toggle="yes">PTCH2</italic>, highly homologous to <italic toggle="yes">PTCH1,</italic> was mapped to chromosome 1p32.1-p32.3 [<xref ref-type="bibr" rid="bcns.REF.smyth.1999.291">Smyth et al 1999</xref>]. Pathogenic variants were found in one simplex case (i.e., a single occurrence of the disease in a family) of medulloblastoma and one simplex case of BCC. No <italic toggle="yes">PTCH2</italic> pathogenic variants were found in 11 simplex cases of NBCCS or in 11 individuals with familial cases of NBCCS who did not have identifiable <italic toggle="yes">PTCH1</italic> pathogenic variants.</p>
          <p>
            <bold>
              <italic toggle="yes">PTCH1</italic>
            </bold>
          </p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">PTCH1</italic> consists of 23 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bcns" object-id="bcns.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> See <xref ref-type="table" rid="bcns.T.frequency_of_pathogenic_genetic_m">Table 2</xref>.</p>
          <table-wrap id="bcns.T.frequency_of_pathogenic_genetic_m" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Frequency of Pathogenic Genetic Mechanisms</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Individuals Affected with NBCCS</th>
                  <th id="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type of Pathogenic Variant</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">65%</td>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Premature termination codon (predicting a protein truncation)</td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">16%</td>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Missense</td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">13%</td>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Splice-site</td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">6%</td>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon or large-scale deletions or rearrangements</td>
                </tr>
                <tr>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Rare&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_bcns.T.frequency_of_pathogenic_genetic_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deep intronic variants that alter splicing</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Source: literature and 395 samples from diagnostic laboratory, Birmingham Women's Hospital, UK, August 2007 (Proportions of types of pathogenic variant have remained the same over several years.)</p>
              </fn>
              <fn id="bcns.TF.2.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="bcns.REF.bholah.2014.477">Bholah et al [2014]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> Protein patched homolog 1 is an integral membrane protein with 12 transmembrane regions, two extracellular loops, and a putative sterol-sensing domain. Protein patched homolog 1 binds the secreted factor sonic hedgehog (SHH) and functions as the SHH receptor. The protein represses the signaling activity of the co-receptor smoothened (SMOH). When in complex with SHH, protein patched homolog 1 is not a repressor, and signaling ensues. At least three forms of the protein patched homolog 1 are present in human cells [<xref ref-type="bibr" rid="bcns.REF.hahn.1996.841">Hahn et al 1996</xref>].</p>
          <p><bold>Abnormal gene product.</bold> Pathogenic variants found in individuals with NBCCS and non-familial BCC include those predicted to result in a truncated protein and missense variants. Rare deep intronic variants that alter splicing are predicted to cause loss of function of protein patched homolog 1 [<xref ref-type="bibr" rid="bcns.REF.bholah.2014.477">Bholah et al 2014</xref>].</p>
          <p>
            <bold>
              <italic toggle="yes">SUFU</italic>
            </bold>
          </p>
          <p><bold>Gene structure.</bold> Alternative splicing results in multiple transcript variants. The longest, comprising 12 exons, is <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_016169.3">NM_016169.3</ext-link>. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bcns" object-id="bcns.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> Missense and nonsense variants, splice consensus sites, and multiexon deletions have been reported [<xref ref-type="bibr" rid="bcns.REF.kijima.2012.565">Kijima et al 2012</xref>, <xref ref-type="bibr" rid="bcns.REF.smith.2014.4155">Smith et al 2014</xref>].</p>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">SUFU</italic> encodes the suppressor of fused homolog protein, which is a negative regulator in the hedgehog signaling pathway. The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_016169.3">NM_016169.3</ext-link> transcript variant encodes the longer isoform <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_057253.2">NP_057253.2</ext-link> with 484 amino acid residues.</p>
          <p><bold>Abnormal gene product.</bold> Heterozygous loss-of-function <italic toggle="yes">SUFU</italic> variants cause NBCCS.</p>
          <sec id="bcns.Cancer_and_Benign_Tumors">
            <title>Cancer and Benign Tumors</title>
            <p>Somatic pathogenic variants in <italic toggle="yes">PTCH1</italic> are involved in a range of sporadically occurring tumors including those observed in NBCCS: keratocysts, BCC, skin trichoepithelioma, medulloblastoma, and ovarian fibroma.</p>
            <p><italic toggle="yes">SUFU</italic> pathogenic variants are usually germline in individuals with medulloblastoma but can occur somatically (far less so than <italic toggle="yes">PTCH1</italic>) and when present confer resistance to SMO inhibition [<xref ref-type="bibr" rid="bcns.REF.kool.2014.393">Kool et al 2014</xref>].</p>
          </sec>
        </sec>
      </sec>
      <sec id="bcns.References">
        <title>References</title>
        <sec id="bcns.Published_GuidelinesConsensus_State">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="bcns.Published_GuidelinesConsensus_State.reflist0">
            <ref id="bcns.REF1">
              <mixed-citation publication-type="web">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jco.ascopubs.org/content/28/5/893.long">online</ext-link>; registration or institutional access required. 2010. Accessed 5-6-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="bcns.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="bcns.Literature_Cited.reflist0">
            <ref id="bcns.REF.alessi.2009.961">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alessi</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanches</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messina</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pimentel</surname>
                    <given-names>ER</given-names>
                  </name>
                </person-group>
                <comment>FestaNeto C</comment>
                <year>2009</year>
                <article-title>Treatment of cutaneous tumors with topical 5% imiquimod cream.</article-title>
                <source>Clinics (Sao Paulo)</source>
                <volume>64</volume>
                <fpage>961</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19841702</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.amlashi.2003.618">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Amlashi</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riffaud</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brassier</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morandi</surname>
                    <given-names>X</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature.</article-title>
                <source>Cancer</source>
                <volume>98</volume>
                <fpage>618</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">12879481</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.bassetseguin.2014.626">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Basset-Seguin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bissonnette</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haedersdal</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lear</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piaserico</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy.</article-title>
                <source>J Eur Acad Dermatol Venereol.</source>
                <year>2014</year>
                <volume>28</volume>
                <fpage>626</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">23581795</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.bholah.2014.477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bholah</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byers</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miles</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <article-title>Intronic splicing mutations in PTCH1 cause Gorlin syndrome.</article-title>
                <source>Fam Cancer.</source>
                <year>2014</year>
                <volume>13</volume>
                <fpage>477</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">24659465</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.black.2003.478">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazerolle</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campsall</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damji</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boutet</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bignon</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drouin-Garraud</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarda</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorry</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Spectrum of PTCH1 mutations in French patients with Gorlin syndrome.</article-title>
                <source>J Invest Dermatol</source>
                <volume>121</volume>
                <fpage>478</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">12925203</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.bree.2011.2091">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bree</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>MR</given-names>
                  </name>
                  <collab>BCNS Colloquium Group</collab>
                </person-group>
                <article-title>Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS).</article-title>
                <source>Am J Med Genet A.</source>
                <year>2011</year>
                <volume>155A</volume>
                <fpage>2091</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21834049</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.brugi_res.2012.2087">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brugi&#x000e8;res</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remenieras</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierron</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varlet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forget</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrde</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bombled</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puget</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufour</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delattre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grill</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age.</article-title>
                <source>J Clin Oncol.</source>
                <year>2012</year>
                <volume>30</volume>
                <fpage>2087</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">22508808</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.cowan.1997.141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoban</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelsey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gattamaneni</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma.</article-title>
                <source>Br J Cancer</source>
                <volume>76</volume>
                <fpage>141</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9231911</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.debeer.2005.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Debeer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devriendt</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Early recognition of basal cell naevus syndrome.</article-title>
                <source>Eur J Pediatr</source>
                <volume>164</volume>
                <fpage>123</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15717175</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.evans.1991a.643">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orton</surname>
                    <given-names>CI</given-names>
                  </name>
                </person-group>
                <year>1991a</year>
                <article-title>Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome.</article-title>
                <source>Br J Neurosurg</source>
                <volume>5</volume>
                <fpage>643</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">1772613</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.evans.1991b.959">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farndon</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnell</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gattamaneni</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>1991b</year>
                <article-title>The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma.</article-title>
                <source>Br J Cancer</source>
                <volume>64</volume>
                <fpage>959</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">1931625</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.evans.1993.460">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ladusans</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimmer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnell</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thakker</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farndon</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.</article-title>
                <source>J Med Genet</source>
                <volume>30</volume>
                <fpage>460</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">8326488</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.evans.2007.424">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DGR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shenton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gokhale</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowers</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mosaicism in NF2 an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including MLPA.</article-title>
                <source>J Med Genet.</source>
                <volume>44</volume>
                <fpage>424</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17307835</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.evans.2010.327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giblin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clancy</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalloo</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>152A</volume>
                <fpage>327</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">20082463</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.farndon.2004">
              <mixed-citation publication-type="book">Farndon PA. Gorlin (naevoid basal cell carcinoma) syndrome. In: Eeles R, Easton DF, Ponder BAJ, Eng C, eds. <italic toggle="yes">Genetic Predisposition to Cancer.</italic> London, UK: Hodder Arnold; 2004:193-213.</mixed-citation>
            </ref>
            <ref id="bcns.REF.goldberg.2011.839">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moody</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kazakevich</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holzer</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Myers</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449.</article-title>
                <source>Arch Dermatol.</source>
                <volume>147</volume>
                <fpage>839</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">21422324</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.gorlin.2004.530">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gorlin</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Nevoid basal cell carcinoma (Gorlin) syndrome.</article-title>
                <source>Genet Med</source>
                <volume>6</volume>
                <fpage>530</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15545751</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.hahn.1996.841">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wicking</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaphiropoulous</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gailani</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chidambaram</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorechovsky</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmberg</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unden</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillies</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Negus</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smyth</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pressman</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leffell</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerrard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toftgard</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chenevix-Trench</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wainwright</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bale</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.</article-title>
                <source>Cell</source>
                <volume>85</volume>
                <fpage>841</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">8681379</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.haylett.2003.337">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haylett</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>JV</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>DNA damage and repair in Gorlin syndrome and normal fibroblasts after aminolevulinic acid photodynamic therapy: a comet assay study.</article-title>
                <source>Photochem Photobiol</source>
                <volume>78</volume>
                <fpage>337</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">14626660</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.itkin.2004.1054">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Itkin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilchrest</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.</article-title>
                <source>Dermatol Surg</source>
                <volume>30</volume>
                <fpage>1054</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15209801</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.jones.2011">
              <mixed-citation publication-type="other">Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in gorlin syndrome: a review of 202 patients. J Skin Cancer. 2011;2011:217378.</mixed-citation>
            </ref>
            <ref id="bcns.REF.kagy.2000.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kagy</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amonette</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.</article-title>
                <source>Dermatol Surg</source>
                <volume>26</volume>
                <fpage>577</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10848940</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.kijima.2012.565">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kijima</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujii</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation.</article-title>
                <source>Fam Cancer.</source>
                <year>2012</year>
                <volume>11</volume>
                <fpage>565</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">22829011</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.kimonis.1997.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kimonis</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastakia</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kase</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiGiovanna</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bale</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bale</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <article-title>Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome.</article-title>
                <source>Am J Med Genet.</source>
                <year>1997</year>
                <volume>69</volume>
                <fpage>299</fpage>
                <lpage>308</lpage>
                <pub-id pub-id-type="pmid">9096761</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.kimonis.2004.495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kimonis</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digiovanna</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bale</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastakia</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome.</article-title>
                <source>Genet Med</source>
                <volume>6</volume>
                <fpage>495</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">15545745</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.klein.2005.611">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dykas</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bale</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory.</article-title>
                <source>Genet Med</source>
                <volume>7</volume>
                <fpage>611</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16301862</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.kool.2014.393">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kool</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000e4;ger</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Northcott</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pugh</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovestadt</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piro</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esparza</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markant</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remke</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milde</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bourdeaut</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryzhova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sturm</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfaff</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stark</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seker-Cin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johann</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bender</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rausch</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shih</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reimand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sieber</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wittmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linke</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witt</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>UD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zapatka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;nig</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beroukhim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergthold</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Sluis</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volckmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koster</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Versteeg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawerenz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartholomae</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Kalle</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unterberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herold-Mende</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulozik</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Deimling</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheurlen</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Felsberg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reifenberger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasselblatt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jabado</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowdrey</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Croul</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zadeh</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korbel</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doz</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delattre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bader</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>VP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kieran</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pomeroy</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witt</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brors</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000fc;ller</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korshunov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eils</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wechsler-Reya</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lichter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfister</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <article-title>ICGC PedBrain Tumor Project. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.</article-title>
                <source>Cancer Cell.</source>
                <year>2014</year>
                <volume>25</volume>
                <fpage>393</fpage>
                <lpage>405</lpage>
                <pub-id pub-id-type="pmid">24651015</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.lo_muzio.2013">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lo Muzio</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastorino</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levanat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musani</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Situm</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi Scarra</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: Gorlin syndrome--update 2013.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2013</year>
                <volume>21</volume>
                <issue>10</issue>
                <pub-id pub-id-type="pmid">23361221</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.loncaster.2009.502">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Loncaster</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swindell</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slevin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheridan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allan</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas.</article-title>
                <source>Clin Oncol (R Coll Radiol)</source>
                <volume>21</volume>
                <fpage>502</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19398312</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.marks.2001.807">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marks</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gebauer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shumack</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amies</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryden</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owens</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.</article-title>
                <source>J Am Acad Dermatol</source>
                <volume>44</volume>
                <fpage>807</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">11312429</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.marsh.2005.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wicking</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wainwright</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chenevix-Trench</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>DHPLC analysis of patients with Nevoid Basal Cell Carcinoma Syndrome reveals novel PTCH missense mutations in the sterol-sensing domain.</article-title>
                <source>Hum Mutat.</source>
                <volume>26</volume>
                <fpage>283</fpage>
                <pub-id pub-id-type="pmid">16088933</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.ming.2002.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ming</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaupas</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roessler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunner</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golabi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tekin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratton</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sujansky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bale</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muenke</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly.</article-title>
                <source>Hum Genet</source>
                <volume>110</volume>
                <fpage>297</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">11941477</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.mohs.1980.777">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohs</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koranda</surname>
                    <given-names>FC</given-names>
                  </name>
                </person-group>
                <year>1980</year>
                <article-title>Microscopically controlled surgery for carcinomas in patients with nevoid basal cell carcinoma syndrome.</article-title>
                <source>Arch Dermatol</source>
                <volume>116</volume>
                <fpage>777</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7396540</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.muller.2012.391">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swaroop</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkin</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chudley</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Everman</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herman</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kivuva</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramanathan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockton</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudgins</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Microdeletion 9q22.3 syndrome includes metopic craniosynostosis, hydrocephalus, macrosomia and developmental delay.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>158A</volume>
                <fpage>391</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22190277</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.nagao.2011.196">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nagao</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujii</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugita</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Endo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motojima</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatsuse</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyashita</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>Entire PTCH1 deletion is a common event in point mutation-negative cases with nevoid basal cell carcinoma syndrome in Japan.</article-title>
                <source>Clin Genet.</source>
                <year>2011</year>
                <volume>79</volume>
                <fpage>196</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21210781</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.oley.1992.799">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharpe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chenevix-Trench</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Basal cell carcinomas, coarse sparse hair, and milia.</article-title>
                <source>Am J Med Genet</source>
                <volume>43</volume>
                <fpage>799</fpage>
                <lpage>804</lpage>
                <pub-id pub-id-type="pmid">1642265</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.oseroff.2005.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oseroff</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shieh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frawley</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheney</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumenson</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pivnick</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellnier</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy.</article-title>
                <source>Arch Dermatol</source>
                <volume>141</volume>
                <fpage>60</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15655143</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.ozgur.2015.220">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ozgur</surname>
                    <given-names>OK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kies</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>William</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Migden</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thuro</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esmaeli</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome.</article-title>
                <source>Am J Ophthalmol.</source>
                <year>2015</year>
                <volume>160</volume>
                <fpage>220</fpage>
                <lpage>7.e2</lpage>
                <pub-id pub-id-type="pmid">25935097</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.pereira.2011.388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pereira</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meneghini</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>AF</given-names>
                  </name>
                </person-group>
                <article-title>BotelhoTde L. Oral diffuse B-cell non-Hodgkin's lymphoma associated to Gorlin-Goltz syndrome: a case report with one year follow-up.</article-title>
                <source>Indian J Pathol Microbiol.</source>
                <year>2011</year>
                <volume>54</volume>
                <fpage>388</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">21623100</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.ponti.2012.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ponti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mignogna</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellacani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastorino</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi-Scarr&#x000e0;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Gregorio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnoni</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzoni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidenari</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Unicysticameloblastoma associated with the novel K729M PTCH1 mutation in a patient with nevoid basal cell carcinoma (Gorlin) syndrome.</article-title>
                <source>Cancer Genet.</source>
                <year>2012</year>
                <volume>205</volume>
                <fpage>177</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">22559979</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.ragge.2005.988">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ragge</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collin</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michalski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farndon</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Gorlin syndrome: the PTCH gene links ocular developmental defects and tumour formation.</article-title>
                <source>Br J Ophthalmol</source>
                <volume>89</volume>
                <fpage>988</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">16024850</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.ratcliffe.1995.596">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ratcliffe</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chenevix-Trench</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS.</article-title>
                <source>Br J Radiol</source>
                <volume>68</volume>
                <fpage>596</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7627481</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.ribeiro.2006.2584">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richieri-Costa</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>PTCH mutations in four Brazilian patients with holoprosencephaly and in one with holoprosencephaly-like features and normal MRI.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>140</volume>
                <fpage>2584</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17001668</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.saran.2010.1003">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling.</article-title>
                <source>Future Oncol.</source>
                <volume>6</volume>
                <fpage>1003</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">20528237</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.sekulic.2012.2171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sekulic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Migden</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oro</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirix</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainsworth</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solomon</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arron</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedlander</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marmur</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudin</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Low</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackey</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yauch</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reddy</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hauschild</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Efficacy and safety of vismodegib in advanced basal-cell carcinoma.</article-title>
                <source>N Engl J Med.</source>
                <volume>366</volume>
                <fpage>2171</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22670903</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.seracchioli.2001.1261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seracchioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bagnoli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colombo</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Missiroli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venturoli</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Conservative treatment of recurrent ovarian fibromas in a young patient affected by Gorlin syndrome.</article-title>
                <source>Hum Reprod</source>
                <volume>16</volume>
                <fpage>1261</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">11387302</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.shanley.1994.282">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shanley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratcliffe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hockey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravine</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wicking</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chenevix-Trench</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Nevoid basal cell carcinoma syndrome: review of 118 affected individuals.</article-title>
                <source>Am J Med Genet</source>
                <volume>50</volume>
                <fpage>282</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">8042673</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.smith.2014.4155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beetz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhaskar</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Sullivan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urquhart</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bholah</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oudit</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheesman</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelsey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations.</article-title>
                <source>J Clin Oncol.</source>
                <year>2014</year>
                <volume>32</volume>
                <fpage>4155</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">25403219</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.smyth.1999.291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smyth</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narang</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heimann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chenevix-Trench</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietsch</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wicking</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wainwright</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene in basal cell carcinoma and medulloblastoma on chromosome 1p32.</article-title>
                <source>Hum Mol Genet</source>
                <volume>8</volume>
                <fpage>291</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9931336</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.stockfleth.2002.569">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stockfleth</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ulrich</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hauschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lischner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christophers</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.</article-title>
                <source>Eur J Dermatol</source>
                <volume>12</volume>
                <fpage>569</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">12459530</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.strong.1977.1861">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>1977</year>
                <article-title>Genetic and environmental interactions.</article-title>
                <source>Cancer</source>
                <volume>40</volume>
                <fpage>1861</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">332332</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.tang.2012.2180">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackay-Wiggan</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aszterbaum</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yauch</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindgren</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coppola</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanana</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marji</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bickers</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>EH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.</article-title>
                <source>N Engl J Med.</source>
                <year>2012</year>
                <volume>366</volume>
                <fpage>2180</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22670904</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.veenstraknol.2005.126">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Veenstra-Knol</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheewe</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Vlist</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Doorn</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ausems</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Early recognition of basal cell naevus syndrome.</article-title>
                <source>Eur J Pediatr</source>
                <volume>164</volume>
                <fpage>126</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">15717176</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.villavicencio.2000.1047">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Villavicencio</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walterhouse</surname>
                    <given-names>DO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The sonic hedgehog-patched-gli pathway in human development and disease.</article-title>
                <source>Am J Hum Genet</source>
                <volume>67</volume>
                <fpage>1047</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11001584</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.watson.2004.716">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Depasquale</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghaderi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zwillenberg</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Nevoid basal cell carcinoma syndrome and fetal rhabdomyoma: a case study.</article-title>
                <source>Ear Nose Throat J</source>
                <volume>83</volume>
                <fpage>716</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15586876</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.wicking.1997.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wicking</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smyth</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillies</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Negus</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suthers</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haites</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wainwright</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chenevix-Trench</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident.</article-title>
                <source>Am J Hum Genet</source>
                <volume>60</volume>
                <fpage>21</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8981943</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.wilding.2012.264">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilding</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingham</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalloo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clancy</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>Life expectancy in hereditary cancer predisposing diseases: an observational study.</article-title>
                <source>J Med Genet.</source>
                <year>2012</year>
                <volume>49</volume>
                <fpage>264</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22362873</pub-id>
              </element-citation>
            </ref>
            <ref id="bcns.REF.yasar.2015.708">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yasar</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byers</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lear</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oudit</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bholah</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome.</article-title>
                <source>Eur J Hum Genet</source>
                <year>2015</year>
                <volume>23</volume>
                <fpage>708</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">25159867</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="bcns.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="bcns.Suggested_Reading.reflist0">
            <ref id="bcns.REF.huret.1997">
              <mixed-citation publication-type="web">Huret JL. Naevoid basal cell carcinoma syndrome (NBCS). <italic toggle="yes">Atlas of Genetics and Cytogenetics Oncology and Haematology</italic>. 1997. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://atlasgeneticsoncology.org/Kprones/NBCID10005.html">online</ext-link>. Accessed 6-5-17.</mixed-citation>
            </ref>
            <ref id="bcns.REF.rees">
              <mixed-citation publication-type="web">Rees JL. Skin cancer (including nevoid basal cell carcinoma syndrome). In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chap 46. McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
            <ref id="bcns.REF.zurada.2005.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zurada</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratner</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Diagnosis and treatment of basal cell nevus syndrome.</article-title>
                <source>Skinmed</source>
                <volume>4</volume>
                <fpage>107</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">15788894</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="bcns.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="bcns.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>1 October 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 March 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 July 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>25 January 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>6 October 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>20 June 2002 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>21 November 2001 (pf) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
